(ACLS) Axcelis Technologies - Overview
Sector: Technology | Industry: Semiconductor Equipment & Materials | Exchange: NASDAQ (USA) | Market Cap: 2.990m USD | Total Return: 89.8% in 12m
Stock
Implanters, Equipment, Services, Parts
Total Rating 60
Risk 73
Buy Signal -0.02
Market Cap:
2,990m
Avg Trading Vol: 57.1M USD
Avg Trading Vol: 57.1M USD
ATR:
5.64%
Peers RS (IBD): 15.3
Peers RS (IBD): 15.3
Risk 5d forecast
Volatility58.7%
Rel. Tail Risk-7.65%
Reward TTM
Sharpe Ratio1.33
Alpha54.61
Character TTM
Beta2.008
Beta Downside1.644
Drawdowns 3y
Max DD78.84%
CAGR/Max DD-0.13
EPS (Earnings per Share)
EPS CAGR: 5.48%
EPS Trend: -23.8%
EPS Trend: -23.8%
Last SUE: 2.81
Qual. Beats: 5
Qual. Beats: 5
Revenue
Rev. CAGR: 4.29%
Rev. Trend: -19.1%
Rev. Trend: -19.1%
Last SUE: 4.00
Qual. Beats: 5
Qual. Beats: 5
Risks
Technicals:
choppy
Description: ACLS Axcelis Technologies
Axcelis Technologies Inc. (ACLS) designs and manufactures ion implantation equipment for semiconductor chip fabrication. This equipment is critical for modifying the electrical properties of silicon wafers, a fundamental step in semiconductor manufacturing.
The company offers a range of implanters categorized by energy levels (high, medium, and high current) to meet diverse application needs. Axcelis also provides aftermarket support, including spare parts, equipment upgrades, and maintenance services, which are common revenue streams in the capital equipment sector.
ACLS sells directly to semiconductor manufacturers globally, with operations in the United States, Europe, and Asia Pacific. Understanding the cyclical nature of the semiconductor industry is key to analyzing companies like Axcelis. Further research on ValueRay can provide deeper insights into ACLSs performance within this dynamic sector.
- Semiconductor capital expenditure directly impacts equipment demand
- Global chip demand drives implanter sales volume
- Aftermarket services revenue provides stable income stream
- Competition in ion implantation market affects pricing
- Supply chain disruptions increase manufacturing costs
Piotroski VR‑10 (Strict)
5.5
| Net Income: 120.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.68 > 1.0 |
| NWC/Revenue: 88.86% < 20% (prev 90.00%; Δ -1.15% < -1%) |
| CFO/TA 0.09 > 3% & CFO 118.3m > Net Income 120.2m |
| Net Debt (-103.1m) to EBITDA (159.9m): -0.64 < 3 |
| Current Ratio: 4.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.1m) vs 12m ago -4.28% < -2% |
| Gross Margin: 44.91% > 18% (prev 0.45%; Δ 4.45k% > 0.5%) |
| Asset Turnover: 61.92% > 50% (prev 75.47%; Δ -13.55% > 0%) |
| Interest Coverage Ratio: 13.17 > 6 (EBITDA TTM 159.9m / Interest Expense TTM 10.8m) |
Altman Z''
7.12
| A: 0.55 (Total Current Assets 943.2m - Total Current Liabilities 197.7m) / Total Assets 1.36b |
| B: 0.37 (Retained Earnings 503.5m / Total Assets 1.36b) |
| C: 0.11 (EBIT TTM 142.3m / Avg Total Assets 1.36b) |
| D: 1.53 (Book Value of Equity 501.4m / Total Liabilities 326.7m) |
| Altman-Z'' Score: 7.12 = AAA |
Beneish M
-2.26
| DSRI: 1.01 (Receivables 168.5m/203.1m, Revenue 839.0m/1.02b) |
| GMI: 0.99 (GM 44.91% / 44.67%) |
| AQI: 2.50 (AQ_t 0.23 / AQ_t-1 0.09) |
| SGI: 0.82 (Revenue 839.0m / 1.02b) |
| TATA: 0.00 (NI 120.2m - CFO 118.3m) / TA 1.36b) |
| Beneish M-Score: -2.26 (Cap -4..+1) = BBB |
What is the price of ACLS shares?
As of April 02, 2026, the stock is trading at USD 93.08 with a total of 580,142 shares traded.
Over the past week, the price has changed by -5.29%, over one month by +10.31%, over three months by +10.90% and over the past year by +89.81%.
Over the past week, the price has changed by -5.29%, over one month by +10.31%, over three months by +10.90% and over the past year by +89.81%.
Is ACLS a buy, sell or hold?
Axcelis Technologies has received a consensus analysts rating of 3.57.
Therefor, it is recommend to hold ACLS.
- StrongBuy: 2
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACLS price?
| Wallstreet Target Price | 92 | -1.2% |
| Analysts Target Price | 92 | -1.2% |
ACLS Fundamental Data Overview
as of 29 March 2026
P/E Trailing = 25.6184 P/E Forward = 26.738
P/S = 3.5641
P/B = 2.9205
P/EG = 1.4493
Revenue TTM = 839.0m USD
EBIT TTM = 142.3m USD
EBITDA TTM = 159.9m USD
Long Term Debt = 40.8m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 1.57m USD (from shortTermDebt, last quarter)
Debt = 42.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -103.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.89b USD (2.99b + Debt 42.3m - CCE 145.5m)
Interest Coverage Ratio = 13.17 (Ebit TTM 142.3m / Interest Expense TTM 10.8m)
EV/FCF = 26.98x (Enterprise Value 2.89b / FCF TTM 107.0m)
FCF Yield = 3.71% (FCF TTM 107.0m / Enterprise Value 2.89b)
FCF Margin = 12.75% (FCF TTM 107.0m / Revenue TTM 839.0m)
Net Margin = 14.33% (Net Income TTM 120.2m / Revenue TTM 839.0m)
Gross Margin = 44.91% ((Revenue TTM 839.0m - Cost of Revenue TTM 462.2m) / Revenue TTM)
Gross Margin QoQ = 46.97% (prev 41.57%)
Tobins Q-Ratio = 2.12 (Enterprise Value 2.89b / Total Assets 1.36b)
Interest Expense / Debt = 3.16% (Interest Expense 1.34m / Debt 42.3m)
Taxrate = 14.30% (5.72m / 40.0m)
NOPAT = 122.0m (EBIT 142.3m * (1 - 14.30%))
Current Ratio = 4.77 (Total Current Assets 943.2m / Total Current Liabilities 197.7m)
Debt / Equity = 0.04 (Debt 42.3m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = -0.64 (Net Debt -103.1m / EBITDA 159.9m)
Debt / FCF = -0.96 (Net Debt -103.1m / FCF TTM 107.0m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.87% (Net Income 120.2m / Total Assets 1.36b)
RoE = 11.72% (Net Income TTM 120.2m / Total Stockholder Equity 1.03b)
RoCE = 13.34% (EBIT 142.3m / Capital Employed (Equity 1.03b + L.T.Debt 40.8m))
RoIC = 11.89% (NOPAT 122.0m / Invested Capital 1.03b)
WACC = 12.91% (E(2.99b)/V(3.03b) * Re(13.05%) + D(42.3m)/V(3.03b) * Rd(3.16%) * (1-Tc(0.14)))
Discount Rate = 13.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.93%
[DCF] Terminal Value 59.42% ; FCFF base≈115.7m ; Y1≈100.6m ; Y5≈80.8m
[DCF] Fair Price = 28.44 (EV 770.6m - Net Debt -103.1m = Equity 873.7m / Shares 30.7m; r=12.91% [WACC]; 5y FCF grow -15.89% → 3.0% )
EPS Correlation: -23.76 | EPS CAGR: 5.48% | SUE: 2.81 | # QB: 5
Revenue Correlation: -19.07 | Revenue CAGR: 4.29% | SUE: 4.0 | # QB: 5
EPS next Quarter (2026-06-30): EPS=0.81 | Chg7d=-0.236 | Chg30d=-0.270 | Revisions Net=-4 | Analysts=5
EPS current Year (2026-12-31): EPS=3.64 | Chg7d=-0.750 | Chg30d=-0.850 | Revisions Net=-5 | Growth EPS=-25.4% | Growth Revenue=+0.1%
EPS next Year (2027-12-31): EPS=4.51 | Chg7d=-0.113 | Chg30d=-0.018 | Revisions Net=-1 | Growth EPS=+23.9% | Growth Revenue=+7.7%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 9.1% (Discount Rate 13.1% - Earnings Yield 3.9%)
[Growth] Growth Spread = -4.6% (Analyst 4.5% - Implied 9.1%)
External Resources